Dr. Chad Deisenroth, PhD, from the US EPA, introduces an advanced human in vitro 3D thyroid microtissue model designed to evaluate thyroid hormone disruption, addressing current challenges with existing models. Developed in collaboration with LifeNet Health, this model offers hormonogenic competence and the capacity to connect mechanistic insights with functional outcomes like thyroid hormone synthesis.

In this webinar, Dr. Deisenroth discusses the US EPA Endocrine Disruptor Screening Program’s (EDSP) approach to screen chemicals for potential thyroid-disrupting effects and the urgent need to advance new approach methods that protect human health while reducing animal testing. He showcases how hormone production in the model mimics human endocrine biology and is inhibited following exposure to known reference chemicals that affect key targets within the thyroid gland.

Dr. Deisenroth also explains the methodology behind establishing minimum donor qualification criteria and benchmark parameters for test method standardization, transferability, and validation. This approach balances performance standardization with the ability to predict a range of human responses.

Lindsey Whaley from LifeNet Health then unveils the first primary human thyrocyte product that enables access to the 3D thyroid microtissue model. Join us for a journey into cutting-edge scientific research that promises to reshape how we assess thyroid disruption.

Key Topics Include:

  • Development of the 3D thyroid microtissue model.
  • Evaluation of model performance, including the production of thyroid hormone.
  • Standardization of the model for thyroid disruption testing.

Presenters

Chad Deisenroth, ;PhD

Chad Deisenroth, PhD

Cell Biologist
Center for Computational Toxicology & Exposure
U.S. Environmental Protection Agency

Dr. Chad Deisenroth is a cell biologist in the Center for Computational Toxicology and Exposure at the U.S. EPA and has 14 years of experience in the development and application of in vitro new approach methods for predictive toxicology.
Lindsey Whaley, ;MS

Lindsey Whaley, MS

Product Manager
LifeSciences
LifeNet Health

As LifeSciences product manager, Lindsey has a passion for driving innovation and delivering exceptional user experiences. Known for her collaborative approach and ability to translate marketing insights into actionable strategies, Lindsey is dedicated to delivering products that align with core customer needs. Lindsey holds a bachelor’s degree in biology and a master’s degree in biotechnology. During her academic journey, she completed two internships at LifeNet Health focused on various LifeSciences marketing projects where she quickly developed a passion for making high-quality, human research solutions accessible to scientific researchers. In her role as Product Manager for LifeNet Health LifeSciences, Lindsey collaborates with cross-functional teams to manage new product releases and an existing portfolio to a global market. She most enjoys using her scientific background to effectively communicate the benefits of LifeSciences’ innovation portfolio to the scientific community.
Watch Webinar

Production Partner

LifeNet Health LifeSciences

LifeNet Health LifeSciences leads the way in human in vitro biology for both non-diseased and diseased research needs. LifeNet Health LifeSciences combines innovative, technology-driven research and development programs to create human tissue and cell-based research products and services.

VIEW PROFILE
LifeNet Health LifeSciences

Additional Content From LifeNet Health LifeSciences

A Novel, All-Human Hepatic Triculture System

A Novel, All-Human Hepatic Triculture System

Join Edward LeCluyse and Paul Gallant as they offer insight into a novel, all-human hepatic triculture and how this unique system addresses the need for a convenient and human-relevant long-term hepatic culture.

Additional Content From Scientist.com

Related Content

Preclinical Animal Models of IBD, GVHD, and Pulmonary Disease

Preclinical Animal Models of IBD, GVHD, and Pulmonary Disease

Join BioModels’ Scientists, Andrew Borkowski, PhD and Nicole Smith, PhD, as they discuss a selection of key preclinical models of inflammatory disease, including models of Inflammatory Bowel Disease (IBD)/colitis, Graft vs Host Disease (GvHD), and pulmonary disease, focusing on the utility of clinically relevant endpoints that create highly translational models of human disease.